NARI Stock Overview
Inari Medical, Inc. builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for NARI from our risk checks.
Inari Medical, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$47.67 |
| 52 Week High | US$71.85 |
| 52 Week Low | US$36.73 |
| Beta | 0.93 |
| 1 Month Change | 25.68% |
| 3 Month Change | -16.51% |
| 1 Year Change | -22.88% |
| 3 Year Change | -45.31% |
| 5 Year Change | n/a |
| Change since IPO | 12.14% |
Recent News & Updates
Recent updates
Is Inari Medical, Inc. (NASDAQ:NARI) Trading At A 29% Discount?
May 02
Inari Medical: Buy On Growing TAM
Mar 27Why We're Not Concerned Yet About Inari Medical, Inc.'s (NASDAQ:NARI) 25% Share Price Plunge
Mar 08Is Now The Time To Look At Buying Inari Medical, Inc. (NASDAQ:NARI)?
Dec 14A Look At The Fair Value Of Inari Medical, Inc. (NASDAQ:NARI)
Oct 23Inari Medical (NASDAQ:NARI) Is In A Strong Position To Grow Its Business
Sep 18Is Inari Medical, Inc. (NASDAQ:NARI) Potentially Undervalued?
Aug 14Inari Medical, Inc. (NASDAQ:NARI) Shares Could Be 23% Above Their Intrinsic Value Estimate
Jul 25We Think Inari Medical (NASDAQ:NARI) Can Afford To Drive Business Growth
Jun 18Inari Medical, Inc.'s (NASDAQ:NARI) Price In Tune With Revenues
Apr 17Is Inari Medical, Inc. (NASDAQ:NARI) Potentially Undervalued?
Dec 07Study assessing Inari Medical's blood clot removal system shows low rate of adverse events
Sep 19Inari Medical: Growth Set To Reaccelerate In The Back Half Of The Year
Sep 07Inari Medical stock falls as Q2 sees net loss; COO to helm company next year
Aug 03Shareholder Returns
| NARI | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 1.4% | -0.2% | -0.2% |
| 1Y | -22.9% | 5.2% | 28.2% |
Return vs Industry: NARI underperformed the US Medical Equipment industry which returned 4.2% over the past year.
Return vs Market: NARI underperformed the US Market which returned 27.7% over the past year.
Price Volatility
| NARI volatility | |
|---|---|
| NARI Average Weekly Movement | 9.2% |
| Medical Equipment Industry Average Movement | 8.3% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 16.0% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: NARI has not had significant price volatility in the past 3 months.
Volatility Over Time: NARI's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 1,300 | Drew Hykes | www.inarimedical.com |
Inari Medical, Inc. builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation. It serves interventional radiologists, interventional cardiologists, and vascular surgeons.
Inari Medical, Inc. Fundamentals Summary
| NARI fundamental statistics | |
|---|---|
| Market cap | US$2.66b |
| Earnings (TTM) | -US$23.62m |
| Revenue (TTM) | US$520.66m |
5.3x
P/S Ratio-117.3x
P/E RatioIs NARI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NARI income statement (TTM) | |
|---|---|
| Revenue | US$520.66m |
| Cost of Revenue | US$64.22m |
| Gross Profit | US$456.44m |
| Other Expenses | US$480.06m |
| Earnings | -US$23.62m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.41 |
| Gross Margin | 87.67% |
| Net Profit Margin | -4.54% |
| Debt/Equity Ratio | 0% |
How did NARI perform over the long term?
See historical performance and comparison